The role of artificial intelligence in postoperative clinical decision-making for pancreatic cancer: a pilot study

• by Samet Yigman, Ahmet Onur Demirel, Ibrahim Halil Ozata, Burak Çelik, Safa Toprak, Salih Karahan, Volkan Adsay, Orhan Bilge, Gürkan Tellioğlu

• June 1, 2026

RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer

At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, presented positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.

• by

• June 1, 2026

• 5 min

Engineered virus-hunter vaccine overcomes HBV immune tolerance

• by Xiaoqing Chen, Xue Liu, Tao Xu, Yalin Wang, Peng Wang, Han Liu, Yichao Jiang, Xiaojing Qin, Liang Zhang, Yueting Xiong, Jiancheng Ding, Yuanzhi Chen, Fentian Chen, Wenjing Ning, Hongye Zeng, Shiting Yang, Lin Xu, Tianying Zhang, Quan Yuan, Chao Liu, Wenxin Luo, Ningshao Xia

• June 1, 2026

Treatment of parotid gland oncocytoma: a case report from a radiation oncologist’s perspective

• by Kemeng Zhao, Feifei Hu, Yong Rui Bai

• June 1, 2026